Cantor Fitzgerald Predicts MannKind FY2026 Earnings

MannKind Co. (NASDAQ:MNKD - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for MannKind in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will earn $0.24 per share for the year. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to analysts' expectations of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The company's quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.05 earnings per share.

Several other research firms have also commented on MNKD. Wall Street Zen lowered MannKind from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of MannKind in a research report on Thursday, February 27th. Finally, Mizuho assumed coverage on shares of MannKind in a research report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $10.00.

MannKind Stock Down 1.2%

Shares of MannKind stock traded down $0.05 during mid-day trading on Tuesday, hitting $3.79. The stock had a trading volume of 666,454 shares, compared to its average volume of 2,386,450. The firm has a 50-day moving average of $4.50 and a two-hundred day moving average of $5.39. The firm has a market cap of $1.15 billion, a P/E ratio of 54.07 and a beta of 1.02. MannKind has a 12-month low of $3.76 and a 12-month high of $7.63.

Institutional Trading of MannKind

Hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of MannKind during the 4th quarter valued at approximately $37,000. Jones Financial Companies Lllp grew its stake in shares of MannKind by 3,294.8% in the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 6,392 shares during the period. Blueshift Asset Management LLC bought a new stake in shares of MannKind during the first quarter valued at approximately $51,000. Sowell Financial Services LLC acquired a new position in MannKind during the first quarter worth $56,000. Finally, Kovitz Investment Group Partners LLC bought a new position in MannKind in the 4th quarter valued at about $65,000. 49.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at MannKind

In related news, Director Steven B. Binder sold 64,085 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $4.00, for a total value of $256,340.00. Following the completion of the sale, the director now owns 925,258 shares in the company, valued at approximately $3,701,032. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP David Thomson sold 32,179 shares of MannKind stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $4.68, for a total value of $150,597.72. Following the transaction, the executive vice president now owns 772,427 shares in the company, valued at approximately $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 190,831 shares of company stock worth $846,298. Corporate insiders own 2.70% of the company's stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.